Analysis of the duration of efficacy and the impact of different dosages of DaliRaSheng (Keweike)

Daridorexant is a new type of dual orexin receptor antagonist (DORA). It mainly blocks orexin OX1R and OX2R receptors, inhibiting neural signals related to the maintenance of wakefulness, thereby improving difficulty in falling asleep and maintaining sleep disorders. Unlike traditional sedative-hypnotics such as benzodiazepines or Z drugs, DaliRazen does not directly inhibit the central nervous system, but promotes natural sleep through the mechanism of "balancing the wake and sleep system", so it is better tolerated and less dependent. The drug was approved by the US FDA in 2022 for the treatment of adult insomnia. It is currently in clinical use in many countries around the world and has shown stable efficacy and low risk of side effects.

Clinical studies have shown that the onset of action of DaliRazen is usually about 30 minutes after taking the drug, and its hypnotic effect can last all night (about 7 to 9 hours) without causing obvious drowsiness or cognitive impairment the next day. A number of randomized controlled trials (such as the IDSI-301 and IDSI-302 studies) have shown that after patients took Dalirasin, not only did they shorten the time it took to fall asleep, reduce the number of nighttime awakenings, and significantly increase the proportion of deep sleep, but also after three months of continuous use, their sleep quality and daytime energy were significantly improved. Compared with traditional drugs, DaliRasen's characteristics of "smooth nighttime effect and good recovery the next day" give it obvious advantages in the long-term treatment of insomnia.

The recommended dose of DaliRasen is 25mg or 50mg taken orally once a day before going to bed. There are certain differences in the efficacy of different doses. Studies have found that the 25mg dose can significantly improve sleep onset latency and total sleep time, while the 50mg dose is more effective in extending sleep duration and reducing nighttime awakenings, but has a slight increase in adverse reactions, such as mild drowsiness, headache or fatigue. Long-term trials have confirmed that there was no obvious drug resistance or rebound after drug withdrawal at both doses, indicating that DaliRazo has a good safety window under dose control. Doctors usually adjust the dosage based on the patient's age, weight and drug sensitivity to achieve the best sleep improvement effect.

Based on the existing data, the efficacy of DaliRasen is not only stable and sustainable, but is especially suitable for patients with long-term chronic insomnia and people with poor tolerance to traditional sleeping pills. For those with mild to moderate insomnia, the dosage of 25 mg is sufficient to provide high-quality sleep throughout the night; for those with sleep maintenance disorders or frequent awakenings at night, you may consider using it50mg dose, but need to monitor for daytime sleepiness. Overall, DaliRasen provides a new option for the treatment of insomnia with its balanced and sustained efficacy, low risk of dependence and good safety. It also represents the future development trend of sleep medicine in the direction of precision and neural regulation.

Reference materials:https://www.drugs.com/